• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The MoCA: A Better MMSE?

The MoCA: A Better MMSE?

May 1, 2008
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD
Most psychiatrists rely on the Folstein Mini Mental State Exam for a rapid, office-based neuropsychological assessment. It is what we were trained on, and we have given it to so many patients that we can pretty much reel off the items from memory.

But the MMSE has some serious limitations. While it is quite sensitive at picking up moderate to severe dementia, it is very poor at screening for patients with mild cognitive impairment (MCI), which is diagnosed in patients who have abnormally poor memory for their age but who do not show significant functional impairment (see TCPR May 2007). Patients with MCI progress to dementia at a rate of 10-15% per year, far higher than the baseline rate of 1-2% per year in normal elderly. In the typical scenario, an elderly patient will come in complaining of memory lapses, and will want to know if they have “normal” age related memory loss or something more serious.

The MMSE is generally unhelpful in such cases, because it’s a little too easy: both normal and MCI patients will typically score 26 or above, the usual cut-off point for cognitive impairment.

But a hot new test, called the Montreal Cognitive Assessment (MoCA) appears to work much better. The test, developed in Quebec with some help from UCLA’s Jeffrey Cummings, was developed specifically to better diagnose MCI. Think of the MoCA as a more challenging version of the MMSE; because it is more challenging, it will pick up a higher proportion
of patients with more subtle amounts of cognitive impairment. Like the MMSE, it is quick to administer (about 10 minutes) and has a maximum of 30 points. In a study comparing the MMSE with the MoCA, the MMSE had a sensitivity of only 18% to detect MCI (meaning it missed 82% of the people with MCI), while the MoCA detected 90% of MCI subjects (Nasreddine ZS et al., J Am Geriatr Soc 2005;53:695-699).

As always, though, high sensitivity comes at the price of somewhat lower specificity (false positives). In the study cited above, for example, the specificity for MCI was 87%, meaning that 13% of actually normal people will be falsely labeled as impaired -- still quite accurate. The really nice thing about the MoCA is that the test and detailed instructions are available (in
several languages) for free at www.mocatest.org. We think the MoCA should become the test of choice for fairly high functioning patients who come in worried about memory loss.

TCPR Verdict:

MoCA: Better than MMSE for mild cognitive impairment.

 
General Psychiatry
KEYWORDS dementia diagnostic_testing
    www.thecarlatreport.com
    Issue Date: May 1, 2008
    SUBSCRIBE NOW
    Table Of Contents
    The MoCA: A Better MMSE?
    Tests to Detect Malingering
    Tamoxifen appears effective for mania
    Orally disintegrating Zyprexa appears to cause less weight gain
    A new study is consistent with FDA’s black box requirements for antidepressants.
    The Utility of Neuropsychological Testing
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.